IOB - Delayed Quote USD

Moderna, Inc. (0A45.IL)

Compare
33.22
-9.65
(-22.51%)
At close: 5:50:43 PM GMT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,056,000.00
6,754,000.00
18,875,000.00
17,736,000.00
274,000.00
Cost of Revenue
1,654,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Gross Profit
3,402,000.00
2,061,000.00
13,459,000.00
15,119,000.00
266,000.00
Operating Expense
6,095,000.00
6,300,000.00
4,039,000.00
1,823,000.00
1,029,000.00
Operating Income
-2,693,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Net Non Operating Interest Income Expense
413,000.00
383,000.00
171,000.00
18,000.00
25,000.00
Other Income Expense
-73,000.00
-86,000.00
-16,000.00
-29,000.00
-6,000.00
Pretax Income
-2,353,000.00
-3,942,000.00
9,575,000.00
13,285,000.00
-744,000.00
Tax Provision
-129,000.00
772,000.00
1,213,000.00
1,083,000.00
3,000.00
Net Income Common Stockholders
-2,224,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Diluted NI Available to Com Stockholders
-2,224,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Basic EPS
-5.81
-12.33
21.26
30.31
-1.96
Diluted EPS
-5.81
-12.33
20.12
28.29
-1.96
Basic Average Shares
382,750.00
382,000.00
394,000.00
403,000.00
381,333.06
Diluted Average Shares
382,750.00
382,000.00
416,000.00
431,000.00
381,333.06
Total Operating Income as Reported
-2,693,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Total Expenses
7,749,000.00
10,993,000.00
9,455,000.00
4,440,000.00
1,037,000.00
Net Income from Continuing & Discontinued Operation
-2,224,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Normalized Income
-2,158,782.83
-4,657,120.00
8,379,460.00
12,202,000.00
-747,000.00
Interest Income
437,000.00
421,000.00
200,000.00
18,000.00
25,000.00
Interest Expense
24,000.00
38,000.00
29,000.00
18,000.00
9,886.00
Net Interest Income
413,000.00
383,000.00
171,000.00
18,000.00
25,000.00
EBIT
-2,329,000.00
-3,904,000.00
9,604,000.00
13,296,000.00
-763,000.00
EBITDA
-1,998,000.00
-3,283,000.00
9,952,000.00
13,528,000.00
-732,000.00
Reconciled Cost of Revenue
1,654,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Reconciled Depreciation
331,000.00
621,000.00
348,000.00
232,000.00
31,000.00
Net Income from Continuing Operation Net Minority Interest
-2,224,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Total Unusual Items Excluding Goodwill
-69,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Total Unusual Items
-69,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Normalized EBITDA
-1,929,000.00
-3,211,000.00
9,972,000.00
13,528,000.00
-732,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,782.83
-15,120.00
-2,540.00
--
--
12/31/2020 - 9/14/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SAR.L Sareum Holdings plc
22.00
-2.22%
 
SANN.SW Santhera Pharmaceuticals Holding AG
12.32
-9.94%
 
VERA Vera Therapeutics, Inc.
33.72
-8.91%
 
APGE Apogee Therapeutics, Inc.
39.94
-2.70%
 
CRNX Crinetics Pharmaceuticals, Inc.
38.46
-5.25%
 
APLS Apellis Pharmaceuticals, Inc.
28.93
+5.43%
 
BNTX BioNTech SE
115.91
-5.65%